PharmiWeb.com

PharmiWeb.com is a news platform that provides global news from organizations across the life science industry. Since its establishment in 1999, it has been widely regarded as Europe's leading life science portal, offering an extensive range of features such as news updates, in-depth articles written by industry experts, event listings and job opportunities. The site is designed and run by PharmiWeb.com Limited, a company registered in England and Wales.

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • Expected product sales for 2024 are approximately $4 billion
  • Moderna expects U.S. approval for its vaccine against respiratory syncytial virus on May 12, with launch expected in the third quarter.
  • Moderna intends to file for approval of its flu vaccine with regulators this year.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

    Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

    Broke On: Thursday, 02 May 2024 Moderna reports Q1 financial results with lower-than-expected loss per share and surpassing sales expectations, thanks to strong Covid vaccine sales. The EU plans to purchase up to 36 million doses annually for four years. Moderna is preparing launches for its RSV vaccine and Spikevax 2024-2025 formula, with potential FDA approval for the RSV vaccine later this quarter.